Eagle Pharmaceuticals Inc (EGRX) — Cash Flow Reinvestment Rate
Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow Reinvestment Rate of 0.00x as of December 2022, reinvesting $19.00K (capex $10.00K plus investments $-9.00K) from operating cash flow of $37.56 Million. Explore reinvestment intensity of Eagle Pharmaceuticals Inc to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eagle Pharmaceuticals Inc Cash Flow Reinvestment Rate (2016–2022)
Historical reinvestment intensity for Eagle Pharmaceuticals Inc across 7 annual periods. Also explore EGRX total asset value for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Eagle Pharmaceuticals Inc (2016–2022)
Year-by-year capital reinvestment analysis for Eagle Pharmaceuticals Inc. For live market cap and broader valuation context, see EGRX company net worth.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 2.83x | $87.01 Million | $30.80 Million | $178.00K | ▲ +1312.1% |
| 2021 | 0.20x | $5.65 Million | $28.22 Million | $323.00K | ▼ -47.9% |
| 2020 | 0.38x | $18.99 Million | $49.50 Million | $747.00K | ▲ +1282.5% |
| 2019 | 0.03x | $1.55 Million | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.01x | $266.00K | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.18x | $10.37 Million | $58.92 Million | $5.19 Million | ▼ -85.9% |
| 2016 | 1.25x | $66.49 Million | $53.21 Million | $20.69 Million | — |